Prelude Therapeutics Crescita futura

Future criteri di controllo 2/6

Si prevede che gli utili di Prelude Therapeutics diminuiranno del 3.3% all'anno, mentre si prevede che il fatturato annuo crescerà del 62.8% all'anno. Si prevede che l'EPS crescerà del 10.1% all'anno.

Informazioni chiave

-3.3%

Tasso di crescita degli utili

10.1%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	27.7%
Tasso di crescita dei ricavi	62.8%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Low
Ultimo aggiornamento	11 Dec 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Sep 16

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 09

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Feb 03

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Sep 17

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

May 28

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Jan 28

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Mar 14

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Dec 14

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Jul 05

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

Feb 16

Prelude Therapeutics prices $150M share offering

Jan 07

Prelude Therapeutics readies public offering

Jan 04

Read This Before Selling Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares

Dec 25

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:PRLD - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	N/A	-175	-143	N/A	2
12/31/2026	N/A	-162	-136	N/A	2
12/31/2025	N/A	-153	-132	N/A	3
12/31/2024	2	-136	-125	N/A	4
9/30/2024	3	-132	-108	-106	N/A
6/30/2024	N/A	-130	-106	-104	N/A
3/31/2024	N/A	-126	-112	-109	N/A
12/31/2023	N/A	-122	-111	-107	N/A
9/30/2023	N/A	-117	-109	-106	N/A
6/30/2023	N/A	-117	-104	-101	N/A
3/31/2023	N/A	-114	-95	-92	N/A
12/31/2022	N/A	-115	-87	-84	N/A
9/30/2022	N/A	-120	-89	-87	N/A
6/30/2022	N/A	-120	-91	-88	N/A
3/31/2022	N/A	-120	-92	-89	N/A
12/31/2021	N/A	-112	-86	-84	N/A
9/30/2021	N/A	-98	-75	-73	N/A
6/30/2021	N/A	-84	-65	-63	N/A
3/31/2021	N/A	-69	-54	-52	N/A
12/31/2020	N/A	-57	-47	-46	N/A
9/30/2020	N/A	-48	-40	-40	N/A
6/30/2020	N/A	-38	-34	-33	N/A
3/31/2020	N/A	-32	-31	-30	N/A
12/31/2019	N/A	-28	-26	-26	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che PRLD rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che PRLD rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che PRLD rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di PRLD ( 62.8% all'anno) crescerà più rapidamente del mercato US ( 9.2% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di PRLD ( 62.8% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di PRLD è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2024/12/31 22:44
Prezzo dell'azione a fine giornata	2024/12/31 00:00
Guadagni	2024/09/30
Guadagni annuali	2023/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Prelude Therapeutics Incorporated è coperta da 7 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Peter Lawson	Barclays
Tazeen Ahmad	BofA Global Research
Graig Suvannavejh	Goldman Sachs

Prelude Therapeutics Crescita futura

Future criteri di controllo 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target decreased by 17% to US$4.80

Price target increased by 12% to US$6.50

Price target decreased by 10.0% to US$5.40

Price target decreased by 9.7% to US$7.00

Price target decreased by 22% to US$7.75

Price target decreased to US$9.60

Recent updates

Founder recently bought US$99k worth of stock

Price target decreased by 17% to US$4.80

Prelude Therapeutics Incorporated Presents Preliminary Results of Phase 1 Dose-Escalation Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Patients with Relapsed/Refractory Lymphoid Malignancies

Price target increased by 12% to US$6.50

Price target decreased by 10.0% to US$5.40

Prelude Therapeutics Incorporated Presents New Data from SMARCA Degrader Portfolio at the 36th EORTC-NCI-AACR Symposium

New minor risk - Market cap size

We're Keeping An Eye On Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics’ SMARCA2 Degrader PRT3789 Demonstrated Promising Initial Clinical Activity and Safety Profile in Phase 1 Trial

Prelude Therapeutics Announces Clinical Collaboration with Merck to Evaluate PRT3789 in Combination with KEYTRUDA® (pembrolizumab) in Patients with SMARCA4-Mutated Cancers

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 14, 2024

Prelude Therapeutics Incorporated Announces Chief Financial Officer Changes

Prelude Therapeutics: Scientifically Interesting Oncology Company With Preclinical Data

Insufficient new directors

Prelude Therapeutics Incorporated announced that it has received $24.999997 million in funding

Prelude Therapeutics Incorporated announced that it expects to receive $24.999997 million in funding

New major risk - Revenue and earnings growth

Price target decreased by 9.7% to US$7.00

New minor risk - Market cap size

Price target decreased by 22% to US$7.75

Prelude Announces Multiple Clinical and Preclinical Poster Presentations at AACR-NCI-EORTC International Conference

New minor risk - Share price stability

Here's Why We're Watching Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

We Think Prelude Therapeutics (NASDAQ:PRLD) Needs To Drive Business Growth Carefully

Founder recently bought US$67k worth of stock

President & Chief Medical Officer exercised options and sold US$81k worth of stock

Here's Why We're Not Too Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Situation

Founder recently bought US$98k worth of stock

Price target decreased to US$9.60

We're Hopeful That Prelude Therapeutics (NASDAQ:PRLD) Will Use Its Cash Wisely

Prelude Therapeutics Incorporated Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader

Prelude wins FDA clearance to start Phase 1 trial for cancer candidate

Prelude downgraded at Morgan Stanley ahead of key update

Price target decreased to US$11.60

We're Not Very Worried About Prelude Therapeutics' (NASDAQ:PRLD) Cash Burn Rate

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 2000 Growth Index

Price target increased to US$30.00

Prelude Therapeutics Incorporated, Annual General Meeting, Jun 17, 2022

Price target decreased to US$25.25

Deborah Morosini Resigns as an Officer of Prelude Therapeutics Incorporated and Will Transition into a Role of Strategic Advisor to the President

Executive VP & Head of Chemistry exercised options to buy US$237k worth of stock.

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Price target increased to US$44.00

Price target decreased to US$38.00

Executive VP & Head of Chemistry recently bought US$95k worth of stock

We Think Prelude Therapeutics (NASDAQ:PRLD) Can Afford To Drive Business Growth

Chief Financial Officer Brian Piper has left the company

Insider exercised options and sold US$87k worth of stock

Price target decreased to US$47.20

Chief Medical Officer exercised options and sold US$436k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$77k worth of stock

Chief Medical Officer notifies of intention to sell stock

Chief Scientific Officer exercised options and sold US$681k worth of stock

Chief Medical Officer exercised options and sold US$384k worth of stock

Companies Like Prelude Therapeutics (NASDAQ:PRLD) Are In A Position To Invest In Growth

Prelude Therapeutics Incorporated(NasdaqGS:PRLD) dropped from Russell 3000E Value Index

Chief Medical Officer exercised options and sold US$458k worth of stock

Chief Financial Officer notifies of intention to sell stock

Chief Medical Officer exercised options and sold US$574k worth of stock

Chief Medical Officer exercised options and sold US$838k worth of stock

Chief Medical Officer exercised options and sold US$725k worth of stock

Chief Medical Officer notifies of intention to sell stock

What Type Of Shareholders Own The Most Number of Prelude Therapeutics Incorporated (NASDAQ:PRLD) Shares?

New 90-day high: US$90.03

Prelude Therapeutics Incorporated Announces Board Changes

Independent Director has left the company

Prelude Therapeutics Incorporated has completed a Follow-on Equity Offering in the amount of $150 million.